EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis

EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin

Related Keywords

Switzerland ,Tomelloso ,Castilla La Manacha ,Spain ,Swiss ,Isabelle Racamier ,Katja Arnold ,Alfredoj Lucendo ,Dennis Burger ,Twitter ,Mc Services ,Us Food Drug Administration ,Department Of Gastroenterology ,Chief Executive ,Hospital General De Tomelloso ,Orphan Drug Designation ,Drug Administration ,